Dr. John Cush RheumNow
5 years 10 months ago
Fibromyalgia Therapies Show Limited Evidence of Pain and QOL Reduction
https://t.co/jpZC4KFygJ https://t.co/k7WFNQg9AY
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @ejdein1 : Dr. Khanna NOVESA study #ACR20 Abst#L09. Autotaxin inhibitor ZIRI in early dcSSc. 21 pts ziri vs 12 PBO. mRSS at Wk24 mean difference -2.8. Ziri well-tolerated. Would be great for new drug for early SSc skin. @RheumNow. https://t.co/TOS9fp4gGK https://t.co/4SDisedzs3
Dr. John Cush RheumNow
5 years 10 months ago
Dr. Conway ( @RichardPAConway) and Dr. Maguire discuss abstract #1323 presented at the #ACR20 on pregnancy in Spondyloarthritis.
https://t.co/YyWOuiq3jn https://t.co/SnodUbKZTx
In this video, Dr. Eric Ruderman looks at abstracts #0884, #0323 and #0909, which focus on disease activity measurement in psoriatic arthritis, presented at the 2020 ACR Convergence meeting earlier this month.
Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events. Virtually every vasculitis patient treated with traditional glucocorticoid regimes suffers from these. These are not minor events with high rates of serious infection and fractures for example.
Dr. John Cush RheumNow
5 years 10 months ago
Timely video on COVID 19 and Rheumatic Disease with Dr. Jeffrey Sparks ( @jeffsparks) #acr20
https://t.co/5Qg3HRkQyW https://t.co/x0iQ6XX3eJ
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @MeralElRamahiMD : Wonder if you can predict development of clinical RA in those at risk either w/ a
- +RF or +CCP
- Relevant sxs w/ or w/o abs
- 1st deg relatives do RA pts?
#ACR20 https://t.co/xVZHxL35UY
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @RADoctor: Adjuvant #herpeszoster vaccine (Shingrix) not effective for 25% of JAKi-treated RA pts (n=40) for antibody response (T cell response usually worse, not reported). Is better than nothing good enough? Maybe we need to hold JAKi briefly?
Dr. John Cush RheumNow
5 years 10 months ago
New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20
https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
"RT @drdavidliew : This - very cool.
Not as impressive as the implanted vagal stimulation pilot data, but once a day and well tolerated. Very early days but enticing, we will see!
#ACR20 ABST1995 @RheumNow https://t.co/cE3gQar0zo https://t.co/bmGnrMGaq3
Dr. John Cush RheumNow
5 years 10 months ago
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate.
https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y
Dr. John Cush RheumNow
5 years 10 months ago
Revisit our #ACR20 coverage. Listen to our Day 3 recap. Follow the link below or find us on Apple/Android podcasts.
https://t.co/IbfY5vbBAo https://t.co/YL9fAuO0oz
Dr. John Cush RheumNow
5 years 10 months ago
#BestACR20Tweets
RT @DrPetryna : #ACR20 Abs L08 Prosp. 4 year PROBE trial of Febuxostat vs allopurinol long term CV safety: febuxostat not associated w/increased risk of death compared w/allopurinol.7.2% pts died in the febuxostat group compared to 8.6% in the allopurinol group
Dr. John Cush RheumNow
5 years 10 months ago
SpA: Etiology to Diagnosis to Treatment - An Abstract Roundup by Dr. Robert Chao ( @doctorRBC) #ACR20
https://t.co/wR0inoR8jp https://t.co/7SFkThkPSr

